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Abstract 
Aim: Liver cirrhosis (LC) is the end stage of chronic liver disease. No definitive 
pharmacological treatment is currently available. We previously reported that 
thrombopoietin (TPO) promoted liver regeneration and improved liver cirrhosis by 
increasing platelet count. TPO is therefore considered to be a therapeutic agent for LC; 
however, it is unclear whether TPO has proliferative effects on hepatocellular carcinoma 
(HCC), which arises frequently in cirrhotic livers. In this study we examined the effects 
of TPO on growth of HCC.  
Methods: Expression of the TPO receptor, myeloproliferative leukemia virus oncogene 
(MPL) was examined in various liver tumor cell lines and liver cell types. In an in vitro 
study, the effects of TPO on signal transduction, cell proliferation, migration, and 
invasion were examined in Huh7 cells, in which MPL is highly expressed. In an in vivo 
study, we subcutaneously transplanted Huh7 cells into nude mice that were divided into 
a TPO-treated group and a control group, and the tumor volume of each group was 
measured. 
Results: MPL was expressed strongly in hepatocytes but not in other cell types. Among 
liver tumor cell lines, Huh7 showed the highest expression of MPL. In Huh7, the 
addition of TPO activated Akt phosphorylation but not cell proliferation, migration, or 
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invasion. In the mouse experiment, there was no significant difference in tumor volume 
between the 2 groups. 
Conclusions: TPO had no proliferative effect on HCC in vitro or in vivo, and could 
therefore be useful in the treatment of liver cirrhosis. 
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Introduction 
Liver cirrhosis (LC) is the end stage of chronic liver disease. It carries a poor 
prognosis, and liver transplantation remains the only curative option. However, there are 
difficulties associated with liver transplantation, including a shortage of donors, high 
cost, transplant rejection, and surgical complications. At present, no definitive 
pharmacological treatment for LC is available, thus increasing the need for development 
of effective therapeutic agents. 
In our previous studies, we demonstrated that platelets promote liver regeneration in 
in vitro
1, 2
 and in vivo
3, 4
 models. We also revealed that platelets reduced liver fibrosis in 
vivo, and platelet-derived adenosine 5'-triphosphate suppressed activation of human 
hepatic stellate cells, which play a critical role in liver fibrosis.
5-7
 Blood transfusion and 
splenectomy are the traditional methods used to increase platelet counts. However, these 
approaches are associated with various difficulties, such as high costs, short storage 
periods, and platelet transfusion refractoriness for transfusions,
8
 and infection and 
thrombosis for splenectomies.
9
 Thrombopoietin (TPO) can increase platelet counts 
independently of blood transfusions and splenectomies, and we therefore considered 
using TPO as a treatment for LC. 
TPO is the major hematopoietic growth factor involved in the proliferation and 
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differentiation of megakaryocytes.
10
 Hepatocytes are the primary site of TPO 
synthesis.
11, 12
 The TPO receptor (TPO-R), myeloproliferative leukemia virus oncogene 
(MPL), is reported to be expressed in liver sinusoidal endothelial cells (LSECs) in mice 
and in liver progenitor cells in rats, and TPO promotes the proliferation of both cell 
types.
13, 14
 Hepatocellular carcinoma (HCC) develops frequently in cirrhotic livers.
15
 
HCC carries a poor prognosis, and it recurs at high rates even after treatment. Therefore, 
it is very important that therapeutic agents for LC have no proliferative effect on HCC. 
It has been reported that TPO increases platelets in the short term clinical study which 
includes HCC patients.
16
 However, there is no report of long term clinical study. Since 
the impact of TPO is unclear in this regard, this study examined the effects of TPO on 
the growth of HCC both in vitro and in vivo. 
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Methods 
Patients and samples 
HCC and non-cancerous liver specimens from 14 patients who underwent 
hepatectomy from August 2006 to March 2009 at Tsukuba University Hospital were 
collected and stored at −80 °C for subsequent analysis by real-time reverse transcription 
polymerase chain reaction (RT-PCR). Liver sections of HCC from these patients were 
also collected and fixed in 10% buffered formalin for later immunohistological analyses. 
The study was approved by the hospital ethics committee and informed consent was 
obtained from all patients. MPL expression was examined in 5 cancerous and 5 
non-cancerous samples from patients with HCC and hepatitis C virus hepatitis, 3 
cancerous and 3 non-cancerous samples from patients with HCC and hepatitis B virus 
hepatitis, and 6 normal liver samples from patients with metastatic tumors. 
 
Cell culture  
Human hepatoblastoma cell lines (HepG2, Hep3B), a human well-differentiated HCC 
cell line (Huh7), human primary hepatocytes, and an immortalized human hepatic 
stellate cell line (TWNT-1) were used in cell cultures. TWNT-1 was kindly donated by 
Dr Kobayashi, Okayama University.
17
 HepG2, Hep3B, Huh7, and TWNT-1 were 
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cultured in Dulbecco’s modified Eagle’s medium (DMEM; Wako Pure Chemical 
Industries, Ltd., Osaka, Japan) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone, Road Logan, UT, USA) and 1% penicillin and streptomycin (Invitrogen, 
Grand Island, NY, USA). The primary hepatocytes, which were purchased from 
XenoTech, LLC (Lenexa, KS, USA), were cultured in Williams’ E medium (Sigma, St. 
Louis, MO, USA) supplemented with 200 µM L-glutamine (Invitrogen), 10% FBS, 100 
µM dexamethasone (Sigma), 1× ITS liquid media supplement (Sigma), and 1% 
penicillin and streptomycin. All cultures were maintained at 37 °C in a humidified 
atmosphere containing 5% CO2. 
 
Total RNA extraction and real-time RT-PCR 
Total RNA was isolated from frozen tissue samples using Isogen reagent (Nippon 
Gene, Tokyo, Japan), and that of whole cells was isolated using the FastPure RNA Kit 
(Takara BIO Inc., Otsu, Japan), in both cases according to the manufacturer’s 
instructions. RNA concentrations were determined by measuring the absorbance at 
260/280 nm with a NanoDrop Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). The synthesis of complimentary DNA was performed using 
AMV Reverse Transcriptase (Promega, Madison, WI, USA) and random primer (Takara 
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BIO, Inc.). Briefly, a mixture of 1 mM dNTPs (Fermentas LIFE SCIENCES, Ontario, 
Canada), 0.025 µg/mL random primer, 0.25 U/µL reverse transcriptase, and 500 ng total 
RNA was incubated at 30 °C for 10 min, 37 °C for 60 min, 95 °C for 5 min, and 4 °C 
before storage at −80 °C. The total RNA of primary LSECs was purchased from 
ScienCell Research Laboratories (Carlsbad, CA, USA) 
 
Quantitative RT-PCR of MPL 
Primers for RT-PCR were designed by Primer Express Software for Real-Time PCR 
version 3.0 (Applied Biosystems, Foster City, CA, USA) using GenBank sequences. 
Primers were purchased from Hokkaido System Science, Ltd. (Hokkaido, Japan). We 
examined MPL and GAPDH (encoding the thrombopoietin receptor and 
glyceraldehyde-3-phosphate dehydrogenase, respectively). RT-PCR was performed 
using SYBR Green Realtime PCR Master Mix-Plus (TOYOBO, Ltd, Osaka, Japan) and 
Applied Biosystems 7300 Real-time PCR system (Applied Biosystems), following the 
procedure recommended by the manufacturers. GAPDH was used as the endogenous 
control. For PCR the following primers were used for amplification: GAPDH 
(NM_002046): 5'-GGAGTCCACTGGCGTCTTCA-3', 
5'-TTCACACCCATGACGAACATG-3'; MPL (NM_005373): 
9 
 
5'-GGTGACCGCTCTGCATCTAG-3', 5'-GCAGGTCTGGAAGTGAGGG-3'. 
 
Immunohistological analysis 
HCC samples were stained with the anti-TpoR/c-Mpl antibody (diluted 1:100; 
Millipore, Billerica, MA, USA). Can Get Signal immunostain Solution (Toyobo) was 
used to enhance the immunohistochemical reaction. After exposure to goat anti rabbit 
antibody (Zymed Laboratories, South San Francisco, CA, USA), peroxidase substrate 
diaminobenzidine was added for staining. All sections were counterstained with 
hematoxylin and observed by light microscopy. 
 
Western blot analysis of transcriptional factors 
Huh7 cells or hepatocytes were precultured in 6-well plates. The medium was then 
changed to serum-free medium (2 mL/well), the cells were cultured for 2 h, and 25 
ng/ml recombinant human TPO (Peprotech, Rocky Hill, NJ, USA) was then added to 
each well. Cells were harvested at 5, 10, 15, 30, and 60 min after the addition of TPO. 
HepG2 and Hep3B cells without TPO were also harvested. For Western blot analysis, 
cell lysates were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane (Millipore). The following 
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antibodies were used as primary antibodies: extracellular signal-related kinase 1 and 2 
(ERK1/2) (9102), phospho-ERK1/2 (9101), protein kinase B (Akt) (9272), phospho-Akt 
(9271), signal transducer and activator of transcription (STAT) 3 (9132), 
phospho-STAT3 (9131), STAT5 (9358), phospho-STAT5 (9359), B-cell lymphoma 2 
(Bcl-2) (2872), Bcl-2-associated X protein (Bax) (2774), cleaved caspase-3 (9661) (Cell 
Signaling, Beverly, MA, USA), and anti-TpoR/c-Mpl antibody (06-944) (Millipore). 
β-actin (4970) (Cell Signaling) was used as the endogenous control. The secondary 
antibody that we used was anti-rabbit immunoglobulin-G horseradish peroxidase-linked 
antibody (Cell Signaling). 
 
Cell proliferation 
A total of 3 × 10
3
 Huh7 cells in 100 μl of DMEM medium supplemented with 10% 
FBS, and 1 × 10
4
 hepatocytes in 100 μl of Williams’ E medium supplemented with 10% 
FBS, were seeded in 96-well plates. After incubation at 37 °C for 24 h, the medium was 
changed to serum-free medium and cells were cultured for an additional 2 h. Different 
concentrations of TPO were then added to each well. After incubation at 37 °C for 24 h, 
cell counts were evaluated using the Cell Counting Kit-8 (Dojin, Kumamoto, Japan) and 
DNA synthesis was evaluated using the bromodeoxyuridine (BrdU) assay kit (Roche 
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Diagnostics GmbH, Penzberg, Germany) according to the manufacturer’s instructions. 
 
Cell migration and invasion assays 
Huh7 cells were assessed for their migration and invasion abilities using a 96-well 
cell migration assay kit (Cultrex; Trevigen, Gaithersburg, MD, USA) and 96-well 
collagen IV cell invasion assay kit (Cultrex; Trevigen). Briefly, to starve Huh7 cells, the 
cells at 80% confluence were incubated in serum-free DMEM medium for 24 h. The 
membranes of the upper chambers were coated with 50 μl of 0.1 × Collagen IV solution 
and incubated for 4 h at 37 °C in 5% CO2 (this process was used only for the invasion 
assay). Next, for both assays, 5 × 10
4
 Huh7 cells in 50 μl of serum-free DMEM medium 
were added to the upper compartment of a simplified Boyden chamber designed with an 
8-μm polyethylene terephthalate membrane separating the top and bottom chambers. 
Fresh DMEM medium containing different concentrations of TPO was added to the 
bottom chamber. After 24 h of incubation at 37 °C and 5% CO2, the medium was 
removed and the cells were washed. One hundred microliters of cell dissociation 
solution/calcein-AM was then added and left to incubate for 1 h. After the calcein-AM 
was taken up by the cells, intracellular esterases cleaved the acetomethylester moiety to 
generate free fluorescent calcein, which was detected by a Varioskan Flash microplate 
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reader (Thermo Fisher Scientific, Waltham, MA, USA) at 485-nm excitation and 
520-nm emission. 
 
Anti-apoptosis assay 
A total of 1 × 10
4
 Huh7 cells in 100 μl of DMEM medium supplemented with 10% 
FBS were seeded in 96-well plates. After incubation at 37 °C for 24 h, the medium was 
changed to serum-free medium and cells were cultured for an additional 2 h. Different 
concentrations of TPO and 0.1 μM of staurosporine (Sigma) were then added to each 
well. After incubation at 37 °C for 24 h, cell counts were evaluated using the Cell 
Counting Kit-8. 
 
Animals 
Female BALB/c nude mice (aged 7–8 weeks, weighing approximately 20 g; CLEA 
Japan, Tokyo, Japan) were used in all experiments. Mice were maintained in a 
temperature-controlled room on a 12 h light–dark cycle, with free access to water and 
standard chow. Animals were divided into 2 groups: a control group (n = 9), consisting 
of mice treated with saline, and a TPO-treated group (n = 8), composed of mice treated 
with TPO. Animal experiments were carried out in a humane manner after receiving 
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approval from the Institutional Animal Experiment Committee of the University of 
Tsukuba and in accordance with the Regulation for Animal Experiments at our 
university and the Fundamental Guidelines for Proper Conduct of Animal Experiments 
and Related Activities in Academic Research Institutions under the jurisdiction of the 
Ministry of Education, Culture, Sports, Science and Technology of Japan. 
 
Induction of thrombocytosis 
To investigate the dose effect on platelet count elevation, TPO was injected 
intraperitoneally at doses of 5, 10, 20, and 75 μg/kg body weight into 4 mice per group, 
5 days before platelet evaluation. Because platelet counts were elevated sufficiently at a 
TPO dose of 20 μg/kg body weight, we carried out the following experiments at this 
dose.  
 
Xenograft model of human HCC cells 
For the xenograft model, Huh7 cells were cultured, dissociated in trypsin, centrifuged, 
washed in phosphate buffered saline (PBS; Wako), and resuspended in PBS. On day 1, 
mice were injected subcutaneously in one rear flank with Huh7 cells, 5 × 10
6
 
cells/mouse.
18
 Nude mice bearing subcutaneous xenografts of Huh7 (typically about 
14 
 
500 mm
3) received intraperitoneal injections of TPO (20 μg/kg body weight) or saline 
on days 14 and 21. Tumors were harvested on day 26. Tumor volume was calculated 
using the following formula: volume (mm
3
) = (d
2
×D)/2, where d is the smallest and D is 
the largest tumor diameter.
19
 Tumor tissue, fixed in 10% buffered formalin, was used for 
histological analyses. Samples were stained in hematoxylin-eosin. 
 
Statistical analysis 
All data are expressed as the means ± standard deviations of samples. Statistical 
analyses were carried out with the Mann-Whitney U-test and one-way ANOVA, and 
significant data were examined using the Bonferroni-Dunn multiple comparisons post 
hoc test. In all cases, p values less than 0.05 were considered significant. 
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Results 
Human MPL expression in tissues and cells 
There were no significant differences in the expression of MPL mRNA between 
cancerous and non-cancerous tissues. MPL expression in hepatitis tissue was 
significantly lower than that in normal liver (Fig. 1A). MPL expression in hepatoma cell 
lines and various liver cell types were also examined using the RT-PCR technique. We 
used the total RNA of HepG2, Hep3B, Huh7, human primary hepatocytes, human 
primary LSECs, and TWNT-1. MPL expression was highest in primary hepatocytes. 
Among the hepatoma cell lines, Huh7 showed the highest expression of MPL (Fig. 1B). 
Therefore, we chose Huh7 cells in subsequent experiments. MPL protein was detected 
in the HCC tissue by immunohistochemistry (Fig. 1C), and in the hepatoma cell lines by 
Western blot analysis (Fig. 1D). 
 
Signal transduction in Huh7 and primary hepatocytes 
In Huh7, the Akt pathway was activated within 5 min after the addition of TPO, while 
TPO did not activate the ERK1/2, STAT3, or STAT5 pathways. In hepatocytes, the 
ERK1/2 and Akt pathways were activated within 15 min after the addition of TPO; the 
STAT3 pathway was slightly activated within 5 min after the addition of TPO, but the 
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STAT5 pathway was not activated by TPO addition (Fig. 2). 
 
Effect of TPO on proliferation, migration, and invasion 
Cell count did not change when Huh7 was incubated with TPO. DNA synthesis by 
Huh7 cells and hepatocytes was not changed by the addition of TPO (Figs. 3A, B). The 
ability of Huh7 cells to migrate through uncoated porous filters (Fig. 3C) or invade 
collagen IV-coated filters (Fig. 3D) in response to TPO was examined in a Boyden 
chamber. TPO did not promote the migration or invasion of Huh7. 
 
Effect of TPO on anti-apoptosis 
We evaluated downstream signals in the Akt pathway. No significant differences in 
levels of Bax, Bcl-2, and cleaved caspase-3 (Fig. 4A) were observed with or without 
TPO. Next, we evaluated the anti-apoptotic effects of TPO after adding staurosporine to 
Huh7 cells. No anti-apoptotic effects were observed, although apoptosis was induced in 
Huh7 cells by staurosporine (Fig. 4B). 
 
Xenograft model  
TPO showed a significant dose-dependent effect on platelet count elevation (Fig. 5A). 
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Transplanted subcutaneous tumors in both groups increased in size daily. There was no 
significant difference in tumor volume (2,914 mm
3
 vs. 2,721 mm
3
, p = 0.793; Fig. 5B) 
or the appearance of tumors (Figs. 5C, D) between the TPO-treated and control groups 
on day 26. Histological examination of tumor tissue from TPO-treated and control 
groups revealed no contrasts in morphology. 
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Discussion 
Liver transplantation is currently the only effective treatment for LC. We previously 
reported that platelets are able to suppress hepatic fibrosis and promote liver 
regeneration. We plan to develop novel treatments for LC by using TPO to increase 
platelet counts in clinical settings. It is necessary to investigate the effects of TPO on 
HCC because HCC is frequently observed in LC patients. In this study, we revealed that 
in humans, MPL expression was lower in HCC cells than in hepatocytes. Although TPO 
stimulated the Akt pathway in an HCC cell line, it did not exert a proliferative effect on 
HCC. In addition, TPO did not promote the growth of HCC in vivo. We conclude, 
therefore, that TPO is useful in the treatment of LC even in individuals with HCC. 
It has been reported that MPL is expressed in various cells and primary tissues. In the 
liver, MPL has been shown to be expressed in rodent hepatic progenitor cells
14
 and 
LSECs
13
, but there are few reports concerning these cells. In humans, several reports 
have demonstrated MPL expression in tissues derived from fetal liver and 
hepatoblastoma.
20-22 
However, as of this writing no studies have examined human tissue 
derived from HCC. In the current report, MPL expression was recognized in HCC 
tissues and was lower than that observed in normal liver. Erickson-Miller et al.
23
 
examined the expression of MPL in 355 various tumor cell lines, including 5 hepatoma 
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cell lines (Hep3B, HepG2, SNU-182, SNU-387, and SNU-475), and found that MPL 
was expressed at very low or undetectable levels in all but 3 of these: 2 erythroleukemia 
cell lines and a lung tumor cell line. Similarly, in our experiment involving a hepatoma 
cell line, MPL expression was observed but was lower than that in hepatocytes. In 
addition, hepatocyte MPL expression occurred at very low levels, approximately 1/30 of 
those seen with a human megakaryocytic leukemia cell line (data not shown). Thus, 
MPL was expressed in HCC but we considered the expression levels to be very low. 
Erythropoietin (EPO) is a hematopoietic growth factor that demonstrates amino acid 
homology with TPO.
24
 The expression of EPO receptor (EPOR) has been demonstrated 
in many cancer cell lines and in tumor tissues.
25, 26
 EPO promotes angiogenesis and 
proliferation and inhibits the apoptosis of tumor cells.
27 
However, 3 studies have shown 
that EPO has no proliferative effect on cancer cell lines.
28-30 
The expression of EPOR in 
tumor cells, therefore, does not necessarily reflect their capacity to accelerate tumor 
growth, nor does it always have a deleterious effect in cancer patients.
25, 31 
Given these 
facts about EPO, and that expression levels of TPO in tumors are much lower than that 
of EPOR,
23
 we speculated that the effects of TPO on tumors are negligible. Additionally, 
Wetzler et al.
32
 showed that there was no correlation between MPL expression and 
functional response to TPO.  
20 
 
TPO is known to function as a growth factor in megakaryocytopoiesis and platelet 
production, and it has also been reported that TPO has proliferative effects on 
non-hematogenous cells, such as venous endothelial cells
33
, hepatic progenitor cells
14
, 
and LSECs
13
. The ability of TPO to stimulate the proliferation of these 
non-hematogenous cells plays an important role in angiogenesis, liver endothelial cell 
repair, and regeneration.
34
 Acute myelogenous leukemia (AML) blast cells express MPL 
and its protein, and TPO exerts a proliferative effect on these cells.
35-37
 Romanelli et 
al.
22
 showed that the migratory activity of hepatoblastoma cells increased in the 
presence of TPO. We examined the ability of TPO to stimulate the migration and 
invasion of HepG2, but found that it did neither (data not shown). Furthermore, TPO 
affected neither DNA synthesis nor cell proliferation in an HCC cell line in our study. 
It is known that TPO activates the Janus tyrosine kinase/STAT pathway, the 
mitogen-activated protein kinase pathway, and the phosphoinositide 3-kinase 
(PI3K)/Akt pathway.
38-40
 PI3K/Akt constitutes an important pathway regulating the 
signaling of multiple biological processes such as apoptosis, metabolism, cell 
proliferation, and cell growth.
41
 Phosphorylated Akt activates glycogen synthase kinase 
3β (GSK3β) by phosphorylation at serine-9, resulting in accumulation of β-catenin and 
cyclin D1 in the nucleus, which induces DNA synthesis and cellular mitosis of 
21 
 
hepatocytes.
42, 43
 On the other hand, other downstream Akt factors play critical roles in 
liver regeneration by regulating cell growth along with activated GSK3β.44-46 In our 
study, TPO did not promote DNA synthesis of hepatocytes, but activated ERK1/2 and 
Akt pathways. It is now well established that the Akt signaling pathway is important for 
cancer growth and metastasis. Several reports have demonstrated the role of the 
PI3K/Akt pathway in the migration of liver cancer cells.
22, 47
 In this study of Huh7, TPO 
activated the phosphorylation of Akt, but neither migration nor invasion activities were 
promoted, and the downstream anti-apoptotic signals of Akt were not activated. TPO 
did not have proliferative or anti-apoptotic effects on Huh7 cells despite the activation 
of Akt. 
Before using TPO as a treatment for LC in the clinical setting, we should consider the 
possibility that it may promote HCC progression. With this in mind, we investigated 
whether or not TPO promoted tumor growth using a murine tumor transplantation 
model. In this experiment, the growth of subcutaneous tumor transplanted in mice was 
not accelerated by TPO treatment. Currently, 2 TPO-R agonists, eltrombopag and 
romiplostim, have been approved for the treatment of chronic immune 
thrombocytopenic purpura. Eltrombopag is a small-molecule, nonpeptide TPO-R 
agonist, while romiplostim is a peptide TPO-R agonist composed of an IgG Fc 
22 
 
fragment.
39
 The efficacy of eltrombopag in HCV-infected patients with 
thrombocytopenia before initiation of pegylated-interferon and ribavirin therapy has 
previously been reported.
48
 However, careful management is necessary, because portal 
vein thrombosis has been reported as a complication of romiplostim.
49
 In contrast to 
TPO, eltrombopag does not activate the PI3K/Akt pathway.
50
 Another report showed 
that eltrombopag has no proliferative effect in myelodysplastic syndromes and AML 
patients,
51
 but rather inhibits the proliferation of leukemia cell lines.
52
 Thus, 
eltrombopag would be secure to the HCC and the use of this type of TPO-R agonist can 
be anticipated as a novel treatment for liver disease. 
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Figure Legends 
Fig. 1. MPL expression in tissues and cells 
(A) Total RNAs of cancerous and non-cancerous tissues were extracted and the 
expression of MPL was measured using real-time reverse transcription polymerase 
chain reaction (RT-PCR). normal liver, normal liver tissue from metastatic liver tumors 
(n = 6); non-ca (HCV), non-cancerous tissues from hepatitis C virus (HCV)-positive 
hepatocellular carcinomas (HCCs) (n = 5); ca (HCV), cancerous tissues from 
HCV-positive HCCs (n = 5); non-ca (HBV), non-cancerous tissues from hepatitis C 
virus (HBV)-positive HCCs (n = 3); ca (HBV), cancerous tissues from HBV-positive 
HCCs (n = 3); n.s., not significant. * p < 0.05 versus normal liver. Data are expressed as 
means ± standard deviations (SDs). 
(B) MPL expression in hepatoma cell lines (HepG2, Hep3B, and Huh7) and liver cell 
types (human primary hepatocytes, human primary liver sinusoidal endothelial cells 
(LSECs), and TWNT-1) were measured using RT-PCR. * p < 0.05 versus hepatocyte. 
Data are expressed as means ± SDs. 
(C) MPL protein expression in HCC tissue by immunohistochemistry. MPL-positive 
cells are stained brown.  
(D) MPL protein expression in hepatoma cell lines by Western blot analysis. 
 
33 
 
Fig. 2. Signal transduction in Huh7 cells and hepatocytes 
Huh7 cells and hepatocytes were harvested at 0, 5, 10, 15, 30, and 60 min after 25 ng/ml 
of TPO was added, and activation of ERK1/2, Akt, signal transducer and activator of 
transcription (STAT) 3, STAT5 and β-actin was examined by Western blotting.  
 
Fig. 3. Effect of TPO on proliferation, migration, and invasion 
Huh7 cells were cultured with TPO for 24 h, and the effect of TPO on Huh7 
proliferation was then evaluated using bromodeoxyuridine (BrdU) (A). The effect of 
TPO on hepatocyte proliferation was also evaluated using BrdU (B). For each group in 
the proliferation assay, n = 8. Huh7 cells were cultured with TPO for 24 h, and then cell 
migration was analyzed with the cell migration assay kit (C) and cell invasion was 
analyzed with the collagen IV cell invasion kit (D). For each group evaluated with the 
migration and invasion assays, n = 4. Data are expressed as means ± SDs. The values 
indicate ratios compared to a 100% value for 0 ng/ml TPO. 
 
Fig. 4. Effect of TPO on anti-apoptosis 
Huh7 cells were harvested at 0, 5, 10, 15, 30, and 60 min after 25 ng/ml of TPO was 
added, and activation of Bax, Bcl-2, and cleaved caspase-3 was examined by Western 
blotting (A). Huh7 cells were cultured with TPO and staurosporine for 24 h, and the 
anti-apoptotic effect of TPO on Huh7 was evaluated using the Cell Counting Kit-8 (B). 
34 
 
Data are expressed as means ± SDs with n = 8 for each group. The values indicate ratios 
compared to a 100% value without TPO or staurosporine. 
 
Fig. 5. Animal model 
Platelet counts are indicated for groups receiving TPO at doses of 0, 5, 10, 20, or 75 
μg/kg body weight, injected intraperitoneally 5 days before measurements. Data are 
expressed as means ± SDs, with n = 4 for each group. ** p < 0.01 versus normal group 
(A). Nude mice bearing subcutaneous xenografts of Huh7 received i.p. injections of 
TPO (20 μg/kg body weight) or saline on days 14 and 21. Tumor volume (mm3) = 
(d
2
×D)/2, where d indicates the smallest tumor diameter while D indicates the largest. 
Data are expressed as means ± SDs, with n = 8–9 for each group (B). Representative 
features of Huh7 cell grafts in control (C) and TPO-treated mice (D) on day 26. 
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